share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

SEC announcement ·  May 31 04:34
Summary by Futu AI
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.